IP Library Granted Patent US 7,138,487
Granted Patent B2
US 7,138,487 · App. 10/810,741 · Granted Nov 21, 2006

Extractive purification of lipopeptide antibiotics

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,138,487
App. No.
10/810,741
Granted
Nov 21, 2006
Kind
B2
Abstract

The present invention provides a rapid and inexpensive method for extractively isolating acidic lipopeptide antibiotics, such as those having a cyclic peptide or cyclic depsipeptide core, in high yield and purity. In particular, there is provided a method of extracting a variety of acidic lipopeptide antibiotics, directly or indirectly, into water immiscible organic solvents by using a divalent cation chelation procedure.

Claims (25)

1. A method for purifying a lipopeptide antibiotic, said method comprising the steps of:

contacting an aqueous solution comprising a lipopeptide antibiotic, a divalent cation, and a pH above the isoelectric point of the lipopeptide antibiotic with an organic solvent, thereby extracting the lipopeptide antibiotic into the organic solvent, wherein the lipopeptide antibiotic is a derivative of any of the following lipopeptide antibiotics: zaomycin, crystallomycin, amphomycin, aspartocin, glumamycin, daptomycin, antibiotic A1437, antibiotic A-21978C, antibiotic A-54145 or tsushimycin, wherein the derivative is not laspartomycin; and

contacting the organic solvent extract of the lipopeptide antibiotic with acid.

2. The method of claim 1 in which the lipopeptide antibiotic is a derivative of amphomycin.

3. The method of claim 1 in which the lipopeptide antibiotic is a derivative of aspartocin.

4. The method of claim 1 in which the lipopeptide antibiotic is a derivative of antibiotic A-21978C or a derivative of daptomycin.

5. The method of claim 1 in which the pH of the aqueous solution of the lipopeptide antibiotic is adjusted to a basic pH.

6. The method of claim 5 in which the molar concentration of divalent cation relative to carboxylate groups in the lipopeptide antibiotic is between about 4:1 and about 10:1.

7. The method of claim 5 in which the adjusted pH is in the range of about pH 8.0 to about pH 9.0.

8. The method of claim 6 in which the divalent cation is selected from the group consisting of Ca2+, Mg2+ and Zn2+.

9. The method of claim 1 further comprising:

extracting the lipopeptide antibiotic into a third aqueous solution;

extracting the lipopeptide antibiotic into a second organic solvent;

extracting the lipopeptide antibiotic into a fourth aqueous solution; and

concentrating the fourth aqueous solution to provide a salt of the lipopeptide antibiotic.

10. The method of claim 9 , wherein the organic extract of the lipopeptide antibiotic is extracted into the third aqueous solution by washing with an aqueous base solution.

11. The method of claim 9 , wherein the third aqueous solution of the lipopeptide antibiotic is extracted into the second organic solvent by acidifying the third aqueous solution of the lipopeptide antibiotic and contacting with the second organic solvent.

12. The method of claim 9 , wherein the salt of lipopeptide antibiotic is acidified to provide a free acid of lipopeptide antibiotic.

13. The method of claim 12 in which the organic solvent and the second organic solvent is 1-butanol.

14. A method of isolating an acidic lipopeptide antibiotic, comprising the steps of:

(a) contacting an aqueous composition comprising a lipopeptide antibiotic and a divalent metal cation with an organic solvent, wherein said aqueous composition has a pH above the isoelectric point of the lipopeptide antibiotic and the lipopeptide antibiotic is a derivative of any of the following lipopeptide antibiotics: zaomycin, crystallomycin, amphomycin, aspartocin, glumamycin, daptomycin, antibiotic A1437, antibiotic A-21978C, antibiotic A-54145 or tsushimycin, wherein the derivative is not laspartomycin;

(b) acidifying the organic phase obtained from step (a); and

(c) contacting the acidified organic phase of step (b) with an aqueous solvent.

15. The method of claim 14 in which steps (a) through (c) are repeated.

16. The method of claim 1 in which the organic extract of the lipopeptide antibiotic is extracted with an aqueous base solution.

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE CORRECT ASSIGNEE'S ADDRESS PREVIOUSLY RECORDED ON REEL 025026 FRAME 0536. ASSIGNOR(S) HEREBY CONFIRMS THE CORRECT ADDRESS OF ASSIGNEE BIOSOURCE PHARM, INC. SHOULD BE SPRING VALLEY, NEW YORK 10977. Recorded Apr 26, 2011
From: BIOWEST THERAPEUTICS INC.
To: BIOSOURCE PHARM, INC.
Reel/Frame 026181/0251 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 23, 2010
From: BIOWEST THERAPEUTICS INC.
To: BIOSOURCE PHARM, INC.
Reel/Frame 025026/0536 →
CHANGE OF NAME Recorded Aug 27, 2010
From: MIGENIX INC.
To: BIOWEST THERAPEUTICS INC.
Reel/Frame 024892/0492 →
CHANGE OF NAME Recorded Aug 25, 2005
From: MICROLOGIX BIOTECH INC.
To: MIGENIX INC.
Reel/Frame 016662/0582 →